VolitionRx Marks Major Milestone with Nu.Q® NETs Biomarker Validation in Sepsis Research

VolitionRx Limited, listed on NYSE AMERICAN as VNRX, has achieved a remarkable feat in the realm of epigenetics and healthcare with the announcement of a peer-reviewed publication focusing on its innovative Nu.Q® NETs H3.1 biomarker. This milestone highlights the ability of the biomarker to serve as an independent predictor for outcomes in critically ill patients suffering from sepsis and septic shock. The findings have been documented in the respected journal Critical Care Medicine and have sparked considerable excitement surrounding the future of sepsis management.

The publication, titled H3.1 Nucleosomes to Predict Renal Replacement Therapy and Mortality in Sepsis, illustrates the biomarker's efficacy in not only predicting 28-day mortality but also in determining the need for renal replacement therapy (RRT) in affected patients. Research indicates that levels of the Nu.Q® NETs H3.1 biomarker are markedly elevated in patients experiencing septic shock compared to those with mere sepsis, revealing a significant correlation with acute kidney injury severity.

Dr. Andrew Retter, Medical Consultant for Volition, expressed the company's pride in having their research featured in such a distinguished journal, stating, "Nu.Q® NETs is a straightforward, affordable, and accessible method designed to detect various conditions linked to NETosis. The capability of this test to predict early mortality and organ dysfunction in sepsis could revolutionize treatment approaches and significantly enhance patient outcomes."

The publication has garnered attention not only due to its clinical findings but also because of an accompanying editorial discussing the broader implications of H3.1 nucleosomes in understanding sepsis. The editorial suggests that whilst the biomarker is a powerful predictive tool, its real value may lie in identifying a distinct group of patients suffering from NET-mediated organ injury. This insight paves the way for more tailored therapeutic interventions.

Professor Michael Bauer from Jena University Hospital, and co-author of the study, emphasized the potential application of Nu.Q® NETs in clinical settings. He stated, "By accurately forecasting a patient's clinical trajectory early on, healthcare professionals can better manage sepsis cases, allowing for timely interventions that could potentially save lives."

Furthermore, the commercial implications of these findings are significant. Remi Rabeuf, VP of Corporate Alliances and Strategic Partnership at Volition, noted the ongoing discussions with major players in the diagnostic field, reinforced by the strong evidential backing from the study. The company believes the market for the Nu.Q® NETs test presents an enormous opportunity, estimating a total addressable market valued at approximately $2.8 billion.

Globally, sepsis remains a critical health concern, responsible for millions of fatalities each year. In 2021 alone, there were an estimated 166 million cases that resulted in 21.4 million deaths, highlighting a pressing need for enhanced diagnostic tools and methodologies.

Effective early detection and treatment of sepsis are crucial, particularly for patients presenting with infections. Success in these areas can lead to significant improvements in public health and patient outcomes.

In conclusion, VolitionRx stands at the forefront of developing innovative solutions for managing sepsis through its groundbreaking Nu.Q® NETs biomarker. As research continues, the hope remains that enhanced diagnostic capabilities will lead to better treatment protocols and ultimately save more lives. For more information about Volition's transformative technology, visit VolitionRx’s website.